Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. (Q38051400)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23057550%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23057550%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

main subject

anti-retroviral agent

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23057550%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Andrew Owen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23057550%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Tim R Cressey

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23057550%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Tim R Cressey

series ordinal

3

1 reference

27 August 2017

language of work or name

1 reference

1 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23057550%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23057550%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23057550%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23057550%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

1501-1522

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23057550%20AND%20SRC:MED&resulttype=core&format=json

Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice.

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Maternal or infant antiretroviral drugs to reduce HIV-1 transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Antiretroviral regimens in pregnancy and breast-feeding in Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pharmacokinetics of antiretrovirals in pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pharmacogenetics of antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Nuclear receptors and drug disposition gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

The effects of pregnancy on ethanol clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Teratogenicity risk of antiretroviral therapy in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Active transport across the human placenta: impact on drug efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Placental drug transporters and their role in fetal protection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Drug Interactions at the Human Placenta: What is the Evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Metabolism of Zidovudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudi

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Characterization of the mechanism of zidovudine uptake by rat conditionally immortalized syncytiotrophoblast cell line TR-TBT.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Impact of pregnancy on abacavir pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Expression of human organic anion transporters in the choroid plexus and their interactions with neurotransmitter metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Mrp4 confers resistance to topotecan and protects the brain from chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

The distribution of the anti-HIV drug, 2'3'-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Myelomeningocele in a child with intrauterine exposure to efavirenz.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pregnancy Outcomes in Women Exposed to Efavirenz and Nevirapine: An Appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Efavirenz in human breast milk, mothers', and newborns' plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Reduced lopinavir exposure during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Lopinavir tablet pharmacokinetics with an increased dose during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

The private sector and HIV/AIDS in Africa: taking stock of 6 years of applied research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Risk factors for severe hyperbilirubinemia in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Short communication: lack of correlation between UGT1A1*6, *28 genotypes, and plasma raltegravir concentrations in Japanese HIV type 1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Use of darunavir and enfuvirtide in a pregnant woman

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Successful prevention of multidrug resistant HIV mother-to-child transmission with enfuvirtide use in late pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Transplacental passage of ritonavir-boosted darunavir in two pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

ATP-binding cassette efflux transporters in human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Molecular evolutionary analysis of ABCB5: the ancestral gene is a full transporter with potentially deleterious single nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)].

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Characterization and identification of steroid sulfate transporters of human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Functional differences in steroid sulfate uptake of organic anion transporter 4 (OAT4) and organic anion transporting polypeptide 2B1 (OATP2B1) in human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Functional analysis of organic cation transporter 3 expressed in human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

New mutations associated with resistance not detected following zidovudine monotherapy in pregnancy when used in accordance with British HIV Association guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Intensive Pharmacokinetics of Zidovudine 200 mg Twice Daily in HIV-1-Infected Patients Weighing Less Than 60 kg on Highly Active Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Pharmacokinetic Study of Saquinavir 500 mg Plus Ritonavir (1000/100 mg Twice a Day) in HIV-Positive Pregnant Women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Efficacy and Tolerability of Zidovudine 200 mg Twice a Day as Part of Combination Antiretroviral Therapy for 96 Weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.138

21 January 2018

Identifiers

DOI

10.2217/PGS.12.138

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23057550%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference